|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MTREX |
Gene summary for MTREX |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MTREX | Gene ID | 23517 |
| Gene name | Mtr4 exosome RNA helicase | |
| Gene Alias | Dob1 | |
| Cytomap | 5q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | P42285 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23517 | MTREX | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.68e-07 | -4.34e-01 | 0.0155 |
| 23517 | MTREX | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.49e-32 | -5.42e-01 | 0.294 |
| 23517 | MTREX | HTA11_99999965104_69814 | Human | Colorectum | MSS | 4.11e-10 | -5.42e-01 | 0.281 |
| 23517 | MTREX | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.12e-29 | -5.42e-01 | 0.3859 |
| 23517 | MTREX | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.59e-07 | -5.42e-01 | 0.2585 |
| 23517 | MTREX | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.54e-31 | -5.42e-01 | 0.3005 |
| 23517 | MTREX | A001-C-207 | Human | Colorectum | FAP | 1.18e-03 | -2.86e-01 | 0.1278 |
| 23517 | MTREX | A015-C-203 | Human | Colorectum | FAP | 8.61e-21 | -3.16e-01 | -0.1294 |
| 23517 | MTREX | A015-C-204 | Human | Colorectum | FAP | 2.66e-04 | -3.10e-01 | -0.0228 |
| 23517 | MTREX | A002-C-201 | Human | Colorectum | FAP | 2.55e-09 | -1.96e-01 | 0.0324 |
| 23517 | MTREX | A002-C-203 | Human | Colorectum | FAP | 2.38e-04 | -9.89e-02 | 0.2786 |
| 23517 | MTREX | A001-C-119 | Human | Colorectum | FAP | 1.02e-04 | -3.23e-01 | -0.1557 |
| 23517 | MTREX | A001-C-108 | Human | Colorectum | FAP | 1.26e-10 | -1.79e-01 | -0.0272 |
| 23517 | MTREX | A002-C-205 | Human | Colorectum | FAP | 3.32e-13 | -2.42e-01 | -0.1236 |
| 23517 | MTREX | A015-C-006 | Human | Colorectum | FAP | 4.80e-08 | -3.18e-01 | -0.0994 |
| 23517 | MTREX | A015-C-106 | Human | Colorectum | FAP | 1.28e-06 | -2.33e-01 | -0.0511 |
| 23517 | MTREX | A002-C-114 | Human | Colorectum | FAP | 1.31e-12 | -3.79e-01 | -0.1561 |
| 23517 | MTREX | A015-C-104 | Human | Colorectum | FAP | 1.53e-19 | -2.29e-01 | -0.1899 |
| 23517 | MTREX | A001-C-014 | Human | Colorectum | FAP | 1.21e-10 | -2.04e-01 | 0.0135 |
| 23517 | MTREX | A002-C-016 | Human | Colorectum | FAP | 1.16e-12 | -2.50e-01 | 0.0521 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001607232 | Thyroid | ATC | rRNA metabolic process | 161/6293 | 236/18723 | 1.02e-27 | 5.89e-25 | 161 |
| GO:000037534 | Thyroid | ATC | RNA splicing, via transesterification reactions | 200/6293 | 324/18723 | 1.75e-25 | 7.39e-23 | 200 |
| GO:000037734 | Thyroid | ATC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 197/6293 | 320/18723 | 6.54e-25 | 2.18e-22 | 197 |
| GO:000039834 | Thyroid | ATC | mRNA splicing, via spliceosome | 197/6293 | 320/18723 | 6.54e-25 | 2.18e-22 | 197 |
| GO:000640127 | Thyroid | ATC | RNA catabolic process | 165/6293 | 278/18723 | 8.45e-19 | 1.14e-16 | 165 |
| GO:003447021 | Thyroid | ATC | ncRNA processing | 216/6293 | 395/18723 | 3.14e-18 | 3.98e-16 | 216 |
| GO:003465525 | Thyroid | ATC | nucleobase-containing compound catabolic process | 217/6293 | 407/18723 | 1.20e-16 | 1.04e-14 | 217 |
| GO:004670024 | Thyroid | ATC | heterocycle catabolic process | 228/6293 | 445/18723 | 7.26e-15 | 4.50e-13 | 228 |
| GO:004427025 | Thyroid | ATC | cellular nitrogen compound catabolic process | 229/6293 | 451/18723 | 2.25e-14 | 1.27e-12 | 229 |
| GO:003466021 | Thyroid | ATC | ncRNA metabolic process | 240/6293 | 485/18723 | 2.03e-13 | 9.91e-12 | 240 |
| GO:001943924 | Thyroid | ATC | aromatic compound catabolic process | 232/6293 | 467/18723 | 3.05e-13 | 1.44e-11 | 232 |
| GO:190136124 | Thyroid | ATC | organic cyclic compound catabolic process | 238/6293 | 495/18723 | 1.12e-11 | 4.12e-10 | 238 |
| GO:000046012 | Thyroid | ATC | maturation of 5.8S rRNA | 24/6293 | 35/18723 | 2.49e-05 | 2.16e-04 | 24 |
| GO:003466111 | Thyroid | ATC | ncRNA catabolic process | 27/6293 | 43/18723 | 8.44e-05 | 6.30e-04 | 27 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa03018 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
| hsa030181 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
| hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |